Management of the cardiorenal syndrome in acute heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 342-355

  Lazzarini, Valentina ^a,b   Felker, G Michael ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Cardiorenal syndrome; Worsening renal function

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENOXIMONE; EPLERENONE; FUROSEMIDE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; MACROLIDE; METOLAZONE; MILRINONE; MINERALOCORTICOID ANTAGONIST; MONOAMINE OXIDASE INHIBITOR; NATRIURETIC FACTOR; NESIRITIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RELAXIN; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VERAPAMIL;

ACUTE HEART FAILURE; ANGIONEUROTIC EDEMA; CARDIORENAL SYNDROME; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIURESIS; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULOSCLEROSIS; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART VENTRICLE OVERLOAD; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPERVOLEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; LOW DRUG DOSE; NAUSEA; NEUROENDOCRINE DISEASE; OTOTOXICITY; PRACTICE GUIDELINE; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC HEART FAILURE; TACHYCARDIA; TREATMENT OUTCOME; ULTRAFILTRATION;

EID: 84865683988     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0186-5     Document Type: Review

References (83)

1. Ronco C, McCullough PA, Anker SD, Acute Dialysis Quality Initiative (ADQI) consensus group, et al. Cardiorenal syndromes: An executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010;165:54-67. Epub 2010 Apr 20.
2. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8(3):136-41. (Pubitemid 34857278)
3. Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: A systematic review. Circ Heart Fail. 2010;3(6):726-45.
4. Breidthardt T, Socrates T, Noveanu M, et al. Effect and clinical prediction of worsening renal function in acute decompensated heart failure. Am J Cardiol. 2011;107(5):730-5. Epub 2011 Jan 19.
5. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61-7. (Pubitemid 38045917)
6. Heywood JT, Fonarow GC, Costanzo MR, ADHERE Scientific Advisory Committee and Investigators, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail. 2007;13(6):422-30. (Pubitemid 47179911)
7. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: Insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268-74. (Pubitemid 351400890)
8. Damman K, Voors AA, Navis G, et al.: Current and novel renal biomarkers in heart failure. Heart Fail Rev. 2011 May 22. [Epub ahead of print]
9. Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: Which drugs can be responsible? J Intern Med. 1999;246:247-52. (Pubitemid 29426443)
10. Hunt SA, Abraham WT, Chin MH, American College of Cardiology Foundation; American Heart Association, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90.
11. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of Angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4(6):685-91. Epub 2011 Sep 8.
12. Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: A systematic review. Circ Heart Fail. 2010;3(6):726-45.
13. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis. J Card Fail. 2007;13(8):599-608. (Pubitemid 47513536)
14. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al.: Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57(22):2233-41. This study assessed the effect of furosemide withdrawal on markers of kidney function and congestion in a small cohort of patients with euvolemic status. Markers of tubular dysfunction increased after diuretic withdrawal and subsequent subclinical congestion, and decreased after restoration of fluid balance.
15. Blair JE, Pang PS, Schrier RW, et al.; EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32(20):2563-72. Epub 2011 Jul 23. This retrospective analysis on the placebo group of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) characterizes a large cohort of patients with WRF during AHF. WRF was associated with poorer outcome but also with a significant decrease in markers of congestion.
16. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265-72. Epub 2010 Jul 6.
17. Testani JM, McCauley BD, Chen J, et al. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail. 2011;17 (12):993-1000. Epub 2011 Oct 1.
18. Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54-62. Epub 2011 Dec 13.
19. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373(9673):1429-39. Epub 2009 Mar 28.
20. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589-96.
21. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9(9):872-8. Epub 2007 Jun 22. (Pubitemid 47332311)
22. Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6(5):966-73. Epub 2011 Mar 10.
23. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002;40(2):221-6. (Pubitemid 34827638)
24. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45(2):268-71. (Pubitemid 40094736)
25. Damman K, van der Harst P, Smilde TD, et al. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart. 2011 Oct 29. [Epub ahead of print]
26. Lassus J, Harjola VP, Sund R, for the FINN-AKVA Study group, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28 (15):1841-7. Epub 2007 Feb 8. (Pubitemid 47236639)
27. Lassus JP, Nieminen MS, Peuhkurinen K, FINNAKVA study group, et al. Markers of renal function and acute kidney injury in acute heart failure: Definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31(22):2791-8. Epub 2010 Aug 27.
28. Damman K, Van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96(16):1297-302.
29. AlvelosM, Lourenço P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2011 Aug 26. [Epub ahead of print]
30. Nymo SH, Ueland T, Askevold ET, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: Results from CORONA(*).J Intern Med. 2011 Dec 28. doi:10.1111/j.1365-2796. 2011.02503.x. [Epub ahead of print]
31. Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705-12. Epub 2011 Jun 11.
32. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13 (8):846-51.
33. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16 (1):49-54. Epub 2009 Aug 21.
34. Breidthardt T, Socrates T, Drexler B, et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care. 2012;16(1):R2 [Epub ahead of print].
35. Dupont M, Awad A, Scarcipino M, et al. Rise in Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Following Intravenous Diuretic Therapy Predicts Development of Worsening Renal Function in Acute Decompensated Heart Failure. Journal of Cardiac Failure, Volume 17, Issue 8, Supplement, August 2011, Pages S24-S25 [abstract]
36. Collins S, Sperling M, Storrow A, et al., Urinary NGAL Levels Predict Acute Kidney Injury in Emergency Department Patients with Acute Heart Failure, Journal of Cardiac Failure, Volume 16, Issue 8, Supplement, August 2010, Pages S29-S30 [abstract]
37. Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1 and N-acetyl-ß-D-glucosaminidase in chronic heart failure: Possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011;13 (10):1104-10. Epub 2011 Aug 16.
38. Dickstein K, Cohen-Solal A, Filippatos G, et al. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J. 2008;29 (19):2388-442. Epub 2008 Sep 17.
39. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22. (Pubitemid 17216948)
40. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: Potential implications in patients with heart failure. Eur J Heart Fail. 2008;10:176-87.
41. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil? Circ. Heart Fail. 2009;2 (1):56-62.
42. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147 (2):331-8. (Pubitemid 38176835)
43. Yilmaz MB, Gayat E, Salem R, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13(11):1244-52.
44. Metra M, Bugatti S, Bettari L, et al. Can we improve the treatment of congestion in heart failure? Expert Opin Pharmacother. 2011;12(9):1369-79. doi:10.1517/ 14656566.2011.557069. Epub 2011 Feb 23.
45. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. This study is the first large randomized trial assessing efficacy and safety of furosemide in acute heart failure. It compared high versus low dose of furosemide and continuous infusion versus intermittent bolus. High dose was more effective in secondary end points associated with fluid loss, without significant differences in the mean change in creatinine levels from baseline to 72 h.
46. Allen LA, Turer AT, Dewald T, et al. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010;105:1794-7.
47. Thomson MR, Nappi JM, Dunn SP, et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16:188-93.
48. Salvator DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;3:CD003178-8.
49. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: A scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12(5):423-33. Epub 2010 Mar 30.
50. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479-87.
51. Klein L, Massie BM, Leimberger JD, OPTIME-CHF Investigators, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1(1):25-33.
52. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510-24.
53. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16:922-30.
54. Kellum JA, Decker JM. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med. 2001;29:15231. Available at Clinicaltrials.gov NCT01132846
55. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-91. (Pubitemid 40470642)
56. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-5. (Pubitemid 40548187)
57. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43. This large randomized trial on nesiritide challenged the use of nesiritide in AHF because it demonstrated a neutral impact of nesiritide on death or rehospitalization, and renal function, and its association with a higher risk of hypotension.
58. Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52(1):60-8. (Pubitemid 351852935)
59. McKie PM, Sangaralingham SJ, Burnett Jr JC. CD-NP: An innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010;7(3):93-9.
60. Pitt B, Zannad F, Remme WJ, for the Randomized Aldactone Evaluation Study Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
61. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. (Pubitemid 36384098)
62. Zannad F, McMurray JJ, Krum H, EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. Epub 2010 Nov 14.
63. Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: Therapeutic potential in acute heart failure syndromes. Eur Heart J. 2011;32 (21):2626-33. Epub 2011 Jun 14.
64. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensinconverting enzyme inhibitor. Am J Cardiol. 1993;71:21A-8A. (Pubitemid 23046408)
65. Ceremuzynski L, Budaj A, Michorowski B. Singledose i.v. Aldactone for congestive heart failure: A preliminary observation. Int J Clin Pharmacol Ther Toxicol. 1983;21:417-21. (Pubitemid 13031149)
66. Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11:441-6.
67. Pitt B, Anker SD, Bushinsky DA, PEARL-HF Investigators, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820-8. Epub 2011 Jan 5.
68. Kamath SA. The role of ultrafiltration in patients with decompensated heart failure. Int J Nephrol. 2010;2011:190230.
69. Ronco C, Giomarelli P. Current and future role of ultrafiltration in CRS. Heart Fail Rev. 2011;16 (6):595-602.
70. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA; Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: Results from UNLOAD. J Card Fail. 2010;16(4):277-84. Epub 2010 Feb 4. This study compared the outcomes of patients with UF versus intravenous diuretics by continuous infusion or bolus injection. Patients undergoing ultrafiltration showed similar fluid loss and similar renal function compared to those with diuretics, but they had fewer hospitalizations for heart failure. Available at Clinicaltrials.gov NCT00608491
71. Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for Acute Heart Failure: A decision model analysis. Circulation. 2009;2 (6):566-73.
72. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: A new target for the treatment of heart failure. Am Heart J. 2003;146:9.
73. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104 (20):2417-23. (Pubitemid 33108374)
74. Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011;17(12):982-9. Epub 2011 Oct 6.
75. KonstamMA, Gheorghiade M, Burnett Jr JC, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297(12):1319-31. Epub 2007 Mar 25.
76. Gheorghiade M, Gattis WA, O'Connor CM, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA. 2004;291(16):1963-71.
77. Slawsky MT, Givertz MM. Rolofylline: A selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2009;10:311-22.
78. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circ. 2002;105:1348-53. (Pubitemid 34260427)
79. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC, CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50(16):1551-60. (Pubitemid 47532320)
80. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: Results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011;57(19):1899-907.
81. Massie BM, O'Connor CM, Metra M, et al.; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419-28. This trial assessed the effect of the promising A1 adenosine receptor antagonist rolofylline, in patients with AHF and renal dysfunction. Compared to placebo, rolofylline showed no benefits on symptoms, prognosis or renal function.
82. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321-9.
83. Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in Acute Heart Failure Study. Am Heart J. 2012;163(2):149-155.e1. This ongoing randomized phase 1/2 clinical trial, following promising results of Pre-RELAX, will provide data about efficacy and safety of relaxin administered at 30 μg/kg/day in patients with AHF, with regard to symptoms, prognosis and renal function.